We have assembled a group of experts in immuno-oncology who advise us in our research and development activities.
We work together to develop breakthrough therapies to treat cancer through improving the immune response.
Our leadership team combine biotech and pharma expertise in immuno-oncology, clinical and corporate strategy to manage the activities of iTeos both in Europe and USA in order to develop and deliver the next generation of cancer immunotherapies.
We have built a Board composed of the different talents to support the growth and differentiation of iTeos as a leader in development of the next generation of cancer immunotherapies by combining expertise in immuno-oncology, clinical strategy, company builders, corporate strategy, finance and commercialization.
